A2780ADR Cell Line
Invented at NIH
A2780 Cell Line
- Datasheet
- References (11)
- Inventor Info
Info
| Catalogue Number | 152706 |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Ovarian cancer cell line |
| Model | Tumour line |
| Relevance |
A2780 cell line used to investigate cisplatin resistance in ovarian cancer. Background and Research Application The A2780 human ovarian cancer cell line was established from tumour tissue from an untreated patient of ovarian endometroid adenocarcinoma. Cells grow as a monolayer and in suspension in spinner cultures. A2780 is the parent line to the cisplatin resistant cell line A2780 cis (catalogue no. 152708) and the adriamycin resistant cell line A2780 ADR (catalogue no. 152707). This cell line has been used in a variety of research, including understanding the role of Snail and Slug in ovarian tumour neovascularization; how to overcome cisplatin resistance in ovarian cancer cells using liposome application and studying the effect of low molecular weight heparin tinzaparin on cisplatin resistance in ovarian cancer cells. |
| Production Details | Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 3-6x10,000cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Adherent |
| Recommended Growing Conditions | RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS). |
| Notes |
Points of Interest A2780 cell line is used in toxicity testing and cancer genetic studies. STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 12,13 D16S539: 11,13 D5S818: 11,12 D7S820: 10 THO1: 6 TPOX: 8,10 vWA: 15,16 Concentration Vial has between 1-5 million cells as standard, however this may vary. |
| Cellosaurus ID | CVCL_0134 |
A2780cis Cell Line
Invented at NIH
References: 11 entries
Nusinow et al. 2020. Cell. 180(2):387-402.e16. PMID: 31978347.
Ghandi et al. 2019. Nature. 569(7757):503-508. PMID: 31068700.
Dutil et al. 2019. Cancer Res. 79(7):1263-1273. PMID: 30894373.
Zhao et al. 2017. Clin Proteomics. 14:20. PMID: 28546799.
Medrano et al. 2017. Cell Rep. 18(10):2343-2358. PMID: 28273451.
Januchowski et al. 2014. Biomed Res Int. 2014:365867. PMID: 24804215.
Han et al. 2013. Oncol Lett. 6(5):1295-1298. PMID: 24179511.
Barretina et al. 2012. Nature. 483(7391):603-7. PMID: 22460905.
Yu et al. 2000. Int J Oncol. 16(3):555-60. PMID: 10675489.
Henkels et al. 1997. Cancer Res. 57(20):4488-92. PMID: 9377558.
Parker et al. 1991. J Clin Invest. 87(3):772-7. PMID: 1999494.
Add a reference
References: 11 entries
Nusinow et al. 2020. Cell. 180(2):387-402.e16. PMID: 31978347.
Ghandi et al. 2019. Nature. 569(7757):503-508. PMID: 31068700.
Dutil et al. 2019. Cancer Res. 79(7):1263-1273. PMID: 30894373.
Zhao et al. 2017. Clin Proteomics. 14:20. PMID: 28546799.
Medrano et al. 2017. Cell Rep. 18(10):2343-2358. PMID: 28273451.
Januchowski et al. 2014. Biomed Res Int. 2014:365867. PMID: 24804215.
Han et al. 2013. Oncol Lett. 6(5):1295-1298. PMID: 24179511.
Barretina et al. 2012. Nature. 483(7391):603-7. PMID: 22460905.
Yu et al. 2000. Int J Oncol. 16(3):555-60. PMID: 10675489.
Henkels et al. 1997. Cancer Res. 57(20):4488-92. PMID: 9377558.
Parker et al. 1991. J Clin Invest. 87(3):772-7. PMID: 1999494.
Add a reference
